Antibodies News and Research

RSS

Kerafast offers the Delta-G-VSV Pseudotyping System for coronavirus research

Kerafast Inc., developers of an online platform to facilitate access to unique lab-made bioresearch materials, today announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, developed by the Michael Whitt laboratory at University of Tennessee, enables studies of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) containment.

From Kerafast 24 Jun 2020

New study defines the transmission of COVID-19 from mother to child

UC Davis Health researchers took a critical step in defining the possible paths for the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causing COVID-19 to get transmitted from the mother to her newborn baby. The mother to fetal transmission is known as "vertical" transmission.

24 Jun 2020

Exposure to SARS-CoV-2 can induce virus-specific T cell responses without seroconversion

A new study by researchers at Strasbourg University Hospital and published on the preprint server medRxiv* in June 2020 shows that COVID-19 antibody responses may sometimes be lacking following exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could lead to a significant underestimation of the number of infections and the number of individuals who have achieved immunity.

24 Jun 2020

Discovery provides a potential target for infectious diseases immunotherapy

NIH investigators and colleagues have discovered that when the immune system first responds to infectious agents such as viruses or bacteria, a natural brake on the response prevents overactivation.

23 Jun 2020

Experts identify steps to expand, improve serology tests for COVID-19

More than 300 scientists and clinicians from the federal government, industry and academia published a report of their conclusions and recommendations on COVID-19 serology studies online in Immunity.

23 Jun 2020

Study highlights the challenges involved in designing universal flu vaccine

Some common strains of influenza have the potential to mutate to evade broad-acting antibodies that could be elicited by a universal flu vaccine, according to a study led by scientists at Scripps Research.

23 Jun 2020

New dengue virus serotype DENV3 has re-emerged in Singapore after three decades

Dengue infections are rising, even as public health authorities are battling to contain the spread of the coronavirus. Dengue virus serotype 2 (DENV2) had previously been the predominant serotype but DENV3 has re-emerged in Singapore after almost three decades.

23 Jun 2020

Male COVID-19 patients produce more SARS-CoV-2 antibodies than women

Health officials in the United Kingdom urge male coronavirus survivors to donate blood, particularly its convalescent plasma component. This comes after a new study has found that men produce more antibodies, which could make their plasma a valuable treatment against the coronavirus disease (COVID-19).

23 Jun 2020

Antibodies against prevalent endemic human coronaviruses may provide cross-protection to SARS-CoV-2

Researchers from Qatar have demonstrated that antibody repertoires against endemic human coronaviruses are qualitatively different in children when compared to the general adult population, as well as healthy adult blood bank donors – and they may also provide cross-protection against epidemic/pandemic strains.

23 Jun 2020

Pangolin version of SARS-CoV-2 can cause COVID-19-like illness

The results of a recent multinational research endeavor, currently available on the bioRxiv preprint server, display the biological framework of SARS-CoV-2-related coronavirus in pangolins and reveal striking similarities to coronavirus disease (COVID-19) in humans, but also show that it can be transmitted vertically to the fetus.

23 Jun 2020

First clinical trial in South Africa for Covid-19 vaccine begins

The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).

23 Jun 2020

White Paper: Separation and characterization of viruses and antibodies

Postnova Analytics have published an informative new white paper that details how multi-detector Asymmetrical Field Flow Fractionation (AF4) and Electrical AF4 (EAF4) techniques are transforming the separation and characterization of viruses and antibodies.

From Postnova Analytics 23 Jun 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

8.5 percent of COVID-19 patients do not seroconvert

A new study published on the preprint server medRxiv in June 2020 reports on the use of inexpensive and accurate ELISA and rapid diagnostic tests (RDT) to identify the demographic and clinical factors that affect the antibody response in COVID-19 patients.

23 Jun 2020

Scientists find COVID-19 antibodies fade quickly

Now, a new study shows that the levels of antibodies found in recovered coronavirus disease (COVID-19) patients declined sharply in just two to three months after infection for both symptomatic and asymptomatic patients.

23 Jun 2020

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

Characterizing SARS-CoV-2 convalescent plasma

A new study published on the preprint server bioRxiv in June 2020 uses serologic correlates to assess the efficacy of convalescent plasma. This will also help to classify donor plasma as more or less potent at neutralizing the virus.

23 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Prior infection provides protection against SARS-CoV-2 virus in hamsters

In an animal model for COVID-19 that shares important features of human disease, scientists at the University of Wisconsin–Madison, the University of Tokyo and the Icahn School of Medicine at Mount Sinai show that prior infection with the SARS-CoV-2 virus provides protection against reinfection, and treatment with convalescent serum limits virus replication in their lungs.

22 Jun 2020

New insights on antibody testing and RNA testing for SARS-CoV-2

Two types of tests are used to track SARS-CoV-2. Reverse transcriptase PCR (rt-PCR) tests for current infection. Antibody tests reveal that an infection has taken place, even long after the fact.

22 Jun 2020